Efficacy and safety of iGlarLixi versus IDegAsp : Results of a systematic literature review and indirect treatment comparison
Diabetes Obesity and Metabolism2021Vol. 23(12), pp. 2660–2669
Citations Over TimeTop 20% of 2021 papers
Philip Home, Roopa Mehta, Khadija Hafidh, Olesya Y. Gurova, Agustina Alvarez, Paul Serafini, Mir‐Masoud Pourrahmat
Abstract
iGlarLixi appears to offer clinical benefit in glucose control and bodyweight change in people needing both basal and meal-time intervention.
Related Papers
- → Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine(2019)
- → Decision letter for "Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta‐analysis and cost‐effectiveness analysis"(2019)
- → Review for "Insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"(2020)
- → Author response for "Insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"(2020)
- → Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L Randomized Clinical Trial"(2020)